{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T06:17:04Z","timestamp":1788675424978,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Obesity Pillars"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.obpill.2026.100302","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:36:53Z","timestamp":1784072213000},"page":"100302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series"],"prefix":"10.1016","volume":"19","author":[{"given":"Spencer","family":"Nadolsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5156-6175","authenticated-orcid":false,"given":"Summer","family":"Kessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8902-8960","authenticated-orcid":false,"given":"Zachary A.","family":"Krumm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0230-6586","authenticated-orcid":false,"given":"Grant M.","family":"Tinsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.obpill.2026.100302_bib1","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000047994","article-title":"GLP-1 receptor agonists for weight loss: a systematic review and meta-analysis of randomized controlled trials","volume":"105","author":"Ahmad","year":"2026","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.obpill.2026.100302_bib2","doi-asserted-by":"crossref","unstructured":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials | Diabetes Care | Am Diabet Associat. https:\/\/diabetesjournals.org\/care\/article\/48\/2\/292\/157724\/Efficacy-of-GLP-1-Receptor-Agonists-on-Weight-Loss.","DOI":"10.2337\/dc24-1678"},{"key":"10.1016\/j.obpill.2026.100302_bib3","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7326\/ANNALS-24-01590","article-title":"Efficacy and safety of glucagon-like Peptide-1 receptor agonists for weight loss among adults without diabetes : a systematic review of randomized controlled trials","volume":"178","author":"Moiz","year":"2025","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.obpill.2026.100302_bib4","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1210\/clinem\/dgz140","article-title":"GLP-1 analog modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity","volume":"105","author":"Kadouh","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.obpill.2026.100302_bib5","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2026.100302_bib6","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41366-019-0348-6","article-title":"Effects of liraglutide on appetite, food preoccupation, and food liking: results of a randomized controlled trial","volume":"44","author":"Tronieri","year":"2020","journal-title":"Int J Obes"},{"key":"10.1016\/j.obpill.2026.100302_bib7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41366-024-01500-y","article-title":"Changes in food preferences and ingestive behaviors after glucagon-like peptide-1 analog treatment: techniques and opportunities","volume":"49","author":"Bettadapura","year":"2025","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.obpill.2026.100302_bib8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/dom.14255","article-title":"Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes","volume":"23","author":"Gibbons","year":"2021","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2026.100302_bib9","article-title":"Glucagon-like peptide 1 receptor agonists in substance use disorders: a systematic review of ClinicalTrials.Gov","volume":"23","author":"Patil","year":"2026","journal-title":"Addict Behav Rep"},{"key":"10.1016\/j.obpill.2026.100302_bib10","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(26)00305-3","article-title":"Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial","volume":"407","author":"Klausen","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.obpill.2026.100302_bib11","doi-asserted-by":"crossref","first-page":"23","DOI":"10.31887\/DCNS.2016.18.1\/wschultz","article-title":"Dopamine reward prediction error coding","volume":"18","author":"Schultz","year":"2016","journal-title":"Dialogues Clin Neurosci"},{"key":"10.1016\/j.obpill.2026.100302_bib12","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.neuron.2012.10.021","article-title":"The mysterious motivational functions of mesolimbic dopamine","volume":"76","author":"Salamone","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.obpill.2026.100302_bib13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41586-022-05614-z","article-title":"Mesolimbic dopamine adapts the rate of learning from action","volume":"614","author":"Coddington","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.obpill.2026.100302_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adr5051","article-title":"An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking","volume":"11","author":"Merkel","year":"2025","journal-title":"Sci Adv"},{"key":"10.1016\/j.obpill.2026.100302_bib15","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/npp.2015.362","article-title":"Glucagon-like Peptide-1 receptor activation in the ventral tegmental area decreases the reinforcing efficacy of cocaine","volume":"41","author":"Schmidt","year":"2016","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.obpill.2026.100302_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.nsa.2025.105512","article-title":"Curbing the appetites and restoring the capacity for satisfaction: the impact of GLP-1 agonists on the reward circuitry","volume":"4","author":"Krupa","year":"2025","journal-title":"Neurosci Appl"},{"key":"10.1016\/j.obpill.2026.100302_bib17","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-026-07045-4","article-title":"Chronic semaglutide treatment enhances the incentive motivational value of a small food reward and associated cue in male and female rats","author":"Chang","year":"2026","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.obpill.2026.100302_bib18","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.neuron.2010.11.022","article-title":"Dopamine in motivational control: rewarding, aversive, and alerting","volume":"68","author":"Bromberg-Martin","year":"2010","journal-title":"Neuron"},{"key":"10.1016\/j.obpill.2026.100302_bib19","doi-asserted-by":"crossref","first-page":"12138","DOI":"10.1073\/pnas.96.21.12138","article-title":"Feeding behavior in dopamine-deficient mice","volume":"96","author":"Szczypka","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.obpill.2026.100302_bib20","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1196\/annals.1417.003","article-title":"Dopamine signaling in the dorsal striatum is essential for motivated behaviors: lessons from dopamine-deficient mice","volume":"1129","author":"Palmiter","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.obpill.2026.100302_bib21","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1093\/brain\/awae214","article-title":"Putaminal dopamine modulates movement motivation in Parkinson's disease","volume":"147","author":"Banwinkler","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.obpill.2026.100302_bib22","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jad.2024.11.019","article-title":"A systematic review in effects of glucagon-like peptide-1 (GLP-1) mono-agonists on functional connectivity: target engagement and rationale for the development in mental disorders","volume":"370","author":"Au","year":"2025","journal-title":"J Affect Disord"},{"key":"10.1016\/j.obpill.2026.100302_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2215-0366(26)00014-3","article-title":"Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: a national cohort study","volume":"13","author":"Taipale","year":"2026","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.obpill.2026.100302_bib24","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/dom.70198","article-title":"Psychiatric effects of GLP\u20101 receptor agonists: a systematic review of emerging evidence","volume":"28","author":"Sa","year":"2026","journal-title":"Diabetes Obes Metabol"},{"key":"10.1016\/j.obpill.2026.100302_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2026.107844","article-title":"The effect of GLP-1 receptor agonists on anxiety: a systematic review","volume":"188","author":"Yi","year":"2026","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.obpill.2026.100302_bib26","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s44220-025-00390-x","article-title":"An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders","volume":"3","author":"De Giorgi","year":"2025","journal-title":"Nat Mental Health"},{"key":"10.1016\/j.obpill.2026.100302_bib27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jagp.2023.08.010","article-title":"The antidepressant effects of GLP-1 receptor agonists: a systematic review and meta-analysis","volume":"32","author":"Chen","year":"2024","journal-title":"Am J Geriatr Psychiatr"},{"key":"10.1016\/j.obpill.2026.100302_bib28","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1001\/jamapsychiatry.2025.0091","article-title":"Suicide and self-harm events with GLP-1 receptor agonists in adults with diabetes or obesity: a systematic review and meta-analysis","volume":"82","author":"Ebrahimi","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.obpill.2026.100302_bib29","first-page":"1","article-title":"GLP-1 receptor agonists and risk of suicide or suicide attempts \u2013 a nationwide cohort and self-controlled case series study","author":"Stanislaus","year":"2026","journal-title":"Mol Psychiatr"},{"key":"10.1016\/j.obpill.2026.100302_bib30","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake","volume":"153","author":"Alhadeff","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.obpill.2026.100302_bib31","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/s41386-018-0010-3","article-title":"Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats","volume":"43","author":"Hernandez","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.obpill.2026.100302_bib32","article-title":"Semaglutide lowers body weight in rodents via distributed neural pathways","volume":"5","author":"Gabery","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.obpill.2026.100302_bib33","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.biopsych.2012.09.001","article-title":"Dual roles of dopamine in food and drug seeking: the drive-reward paradox","volume":"73","author":"Wise","year":"2013","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.obpill.2026.100302_bib34","doi-asserted-by":"crossref","DOI":"10.1002\/cph4.70129","article-title":"GLP-1 at the metabolic-cognitive interface: reward, affect, and memory","volume":"16","author":"Gao","year":"2026","journal-title":"Compr Physiol"},{"key":"10.1016\/j.obpill.2026.100302_bib35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cobeha.2016.02.005","article-title":"GLP-1 influences food and drug reward","volume":"9","author":"Hayes","year":"2016","journal-title":"Curr Opin Behav Sci"},{"key":"10.1016\/j.obpill.2026.100302_bib36","article-title":"Do GLP-1 receptor agonists alter brain responses to reward-related cues?","author":"Dang","year":"2026","journal-title":"A System Rev bioRxiv"},{"key":"10.1016\/j.obpill.2026.100302_bib37","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.2337\/dbi21-0004","article-title":"The role of GIP in the regulation of GLP-1 satiety and nausea","volume":"70","author":"Hayes","year":"2021","journal-title":"Diabetes"},{"key":"10.1016\/j.obpill.2026.100302_bib38","first-page":"1","article-title":"Dissociable hindbrain GLP1R circuits for satiety and aversion","author":"Huang","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.obpill.2026.100302_bib39","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2026.0594","article-title":"Semaglutide and effort-based decision-making in major depressive disorder: a randomized clinical trial","author":"Gill","year":"2026","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.1016\/j.obpill.2026.100302_bib40","article-title":"The GLP-1R agonist semaglutide reduces motivated running and alters dopamine dynamics in the nucleus accumbens","volume":"10","author":"Foscue","year":"2025","journal-title":"bioRxiv"},{"key":"10.1016\/j.obpill.2026.100302_bib41","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1523\/JNEUROSCI.0028-23.2023","article-title":"From prediction to action: dissociable roles of ventral tegmental area and substantia nigra dopamine neurons in instrumental reinforcement","volume":"43","author":"Fraser","year":"2023","journal-title":"J Neurosci"},{"key":"10.1016\/j.obpill.2026.100302_bib42","doi-asserted-by":"crossref","first-page":"19900","DOI":"10.1073\/pnas.1116727109","article-title":"Role of prefrontal cortex and the midbrain dopamine system in working memory updating","volume":"109","author":"D'Ardenne","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.obpill.2026.100302_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2012.04.018","article-title":"The role of prefrontal dopamine D1 receptors in the neural mechanisms of associative learning","volume":"74","author":"Puig","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.obpill.2026.100302_bib44","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.tics.2018.12.006","article-title":"Dopamine and cognitive control in prefrontal cortex","volume":"23","author":"Ott","year":"2019","journal-title":"Trends Cognit Sci"},{"key":"10.1016\/j.obpill.2026.100302_bib45","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.cell.2015.07.015","article-title":"Circuit architecture of VTA dopamine neurons revealed by systematic input-output mapping","volume":"162","author":"Beier","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.obpill.2026.100302_bib46","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.neuron.2017.12.022","article-title":"Nucleus accumbens subnuclei regulate motivated behavior via direct inhibition and disinhibition of VTA dopamine subpopulations","volume":"97","author":"Yang","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.obpill.2026.100302_bib47","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/j.cub.2020.05.003","article-title":"Ventral tegmental dopamine neurons control the impulse vector during motivated behavior","volume":"30","author":"Hughes","year":"2020","journal-title":"Curr Biol"},{"key":"10.1016\/j.obpill.2026.100302_bib48","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/npp.2014.285","article-title":"Dopamine antagonism decreases willingness to expend physical, but not cognitive, effort: a comparison of two rodent cost\/benefit decision-making tasks","volume":"40","author":"Hosking","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.obpill.2026.100302_bib49","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0166-4328(87)90022-2","article-title":"Separation of the motivational and motor consequences of 6-hydroxydopamine lesions of the mesolimbic or nigrostriatal system in rats","volume":"23","author":"Papp","year":"1987","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.obpill.2026.100302_bib50","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1037\/a0014625","article-title":"Dopamine modulates effort-based decision-making in rats","volume":"123","author":"Bardgett","year":"2009","journal-title":"Behav Neurosci"},{"key":"10.1016\/j.obpill.2026.100302_bib51","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13543784.2025.2472408","article-title":"The promise of glucagon-like peptide 1 receptor agonists (GLP-1RA) for the treatment of obesity: a look at phase 2 and 3 pipelines","volume":"34","author":"Madsbad","year":"2025","journal-title":"Expert Opin Invest Drugs"}],"container-title":["Obesity Pillars"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667368126000586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:30:39Z","timestamp":1787988639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667368126000586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":51,"alternative-id":["S2667368126000586"],"URL":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100302","relation":{},"ISSN":["2667-3681"],"issn-type":[{"value":"2667-3681","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series","name":"articletitle","label":"Article Title"},{"value":"Obesity Pillars","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.obpill.2026.100302","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of Obesity Medicine Association.","name":"copyright","label":"Copyright"}],"article-number":"100302"}}